Filter posts

Deal Structures: More Options for Companies

By most measures, 2014 was a great year for the biotechnology industry. Venture capital deal …

Chinese In-Licensing Continues to Strengthen

Chinese companies are eager to collaborate with their ex-China counterparts, and in-licensing agreements are outpacing …

BIO-Europe Spring Opening Remarks

BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring …

Putting a Ring on It: Advice on Successful Drug Development Collaborations

Drug development partnerships can look lucrative to small biotechs eager to monetize their discoveries, but, …

Biobuck M&A in Full Gear

The 2012 M&A results are in and trends are mixed. Last year was a down …

BIO Europe Spring 2012 - Opening Remarks

For Monday’s Opening Remarks at BIO Europe Spring 2012, I covered the following topics: Public …

Venture Capital increases in 2011, but...

The National Venture Capital Association (NVCA) has released their 4Q 2011 numbers for biotech venture …

Where's the Deal?

With only two weeks to go in 2011 it is looking like a five year …

Anitbody Deals Peaked in 2007

Antibody and antibody-like scaffold molecules have been on the pharma licensing radar for some time. …